

=> file reg; d stat que 16

FILE 'REGISTRY' ENTERED AT 11:55:17 ON 12 APR 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 11 APR 2000 HIGHEST RN 261642-55-1





DICTIONARY FILE UPDATES: 11 APR 2000 HIGHEST RN 261642-55-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

L4 STR



VAR G1=18/OH/20/COOH/31/36

VAR G2=O/S

VAR G4=H/29

VAR G5=H/X/24/CF3/ME/OH/COOH/41/44/49/51

VAR G6=H/X

NODE ATTRIBUTES:

NSPEC	IS	RC	AT	26
NSPEC	IS	RC	AT	30
CONNECT	IS	E1	RC	AT 34
CONNECT	IS	E1	RC	AT 38
CONNECT	IS	E1	RC	AT 43
CONNECT	IS	E2	RC	AT 44
CONNECT	IS	E1	RC	AT 47
CONNECT	IS	E2	RC	AT 49

Searched by Toby Port & Barb O'Bryen

CONNECT IS E2 RC AT 51
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE
L6 37 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 2828 ITERATIONS
SEARCH TIME: 00.00.04

37 ANSWERS

=> fil caplus; d que nos 17
FILE 'CAPLUS' ENTERED AT 11:55:34 ON 12 APR 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 12 Apr 2000 VOL 132 ISS 16
FILE LAST UPDATED: 11 Apr 2000 (20000411/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.


L4 STR
L6 37 SEA FILE=REGISTRY SSS FUL L4
L7 3 SEA FILE=CAPLUS ABB=ON PLU=ON L6

=> d ibib abs hitstr 17 1-3; file caold; d que nos 18; file home

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1997:650255 CAPLUS
DOCUMENT NUMBER: 127:303336
TITLE: Phospholipase A2 inhibitors as inhibitors of angiogenesis
INVENTOR(S): Jackson, Jeffrey A.; Winkler, James D.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA; Jackson, Jeffrey A.; Winkler, James D.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
Searched by Toby Port & Barb O'Bryen

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735567	A1	19971002	WO 1997-US4876	19970326
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 904069	A1	19990331	EP 1997-917625	19970326
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
PRIORITY APPLN. INFO.:			US 1996-14244	19960326
			WO 1997-US4876	19970326
OTHER SOURCE(S):		MARPAT 127:303336		
GI				




AB Phospholipase A2 (PLA2) inhibitors are useful for treatment of chronic diseases which are caused by excessive, undesired, or inappropriate angiogenesis, including diabetic retinopathy and other ocular neovascularization, tumor growth and metastasis, and atherosclerosis. The PLA2 inhibitors include compds. which inhibit the transcription, translation, or activity of 14-kDa PLA2, esp. di-Ph ethers or thioethers I [X = O, S; R1 = (CH2)nOH, (CH2)nCO2R8; R2 = H, halo, (substituted) C1-8 alkyl or alkoxy; R3 = SO2R7; R4 = H, SO2R7; R5 = H, halo, CF3, Me, (CH2)tOH, (CH2)tCO2R9; R6 = H, halo; R7 = (substituted) aryl, aralkyl, C1-8 alkyl; R8, R9 = H, C1-4 alkyl; n = 0, 1; m, t = 0-2]. Thus, in the mouse air pouch granuloma model of chronic inflammation with intense angiogenesis, I (50 .mu.M) markedly decreased the vascular index.

IT **173983-49-8**

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (phospholipase A2 inhibitors as inhibitors of angiogenesis)

RN 173983-49-8 CAPLUS

CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9704765	A1	19970213	WO 1996-US12257	19960724
W: JP, US				
EP 841910	A1	19980520	EP 1996-925501	19960724
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 11511130	T2	19990928	JP 1996-507752	19960724
			US 1995-2239	19950725
PRIORITY APPLN. INFO.:			WO 1996-US12257	19960724

AB CoA-independent transacylase (CoA-IT) inhibitors are disclosed for inhibiting or reducing cell proliferation in a human or mammal. Comps. for inhibiting proliferation or inducing apoptosis exclude 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (I) or alkyl lysophospholipid analogs, but the I and analogs are disclosed for treatment of other CoA-IT-mediated diseases. Prepn. of e.g. di-Et 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptanephosphonate (II) is described. II inhibited CoA-IT at a concn. of 9 .mu.M; II also showed apoptosis-inducing activity. The specific inhibition of CoA-IT by I is also described.


IT 173983-49-8P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(comps. for inhibition of CoA-independent transacylase, induction of apoptosis, treating CoA-independent transacylase-dependent diseases and inhibiting cell proliferation, and combd. prepn.)
Searched by Toby Port & Barb O'Bryen

RN 173983-49-8 CAPLUS
 CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1996:134121 CAPLUS
 DOCUMENT NUMBER: 124:165246
 TITLE: Aryl anti-inflammatory compounds, their preparation, and their activity
 INVENTOR(S): Adams, Jerry Leroy; Hall, Ralph Floyd; Lee, Dennis; Mayer, Ruth Judik; Seibel, George Leslie
 PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533461	A1	19951214	WO 1995-US7010	19950602
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5545669	A	19960813	US 1994-252717	19940602
EP 799198	A1	19971008	EP 1995-922184	19950602
R: BE, CH, DE, FR, GB, IT, NL				
JP 10501240	T2	19980203	JP 1995-501221	19950602
PRIORITY APPLN. INFO.:				
			US 1994-252717	19940602
			WO 1995-US7010	19950602
OTHER SOURCE(S): MARPAT 124:165246				
GI				



I


AB The invention relates to the novel compds. and pharmaceutical compns. of I
 [R1 = (CH2)nOH, (CH2)nCO2R8; n = 0, 1; X = O, S; R2 = H, halo,
 (substituted) C1-8 alkyl, C1-8 alkoxy; m = 1, 2; R3 = S(O)2R7; R4 = H,
 S(O)2R7; R5 = H, halo, CF3, Me, (CH2)tC(O)2R9, (CH2)tOH; t = 0-2; R6 = H,
 halo; R7 = (substituted) aryl, (substituted) aryl-C1-2 alkyl,
 (substituted) C1-8 alkyl; R8, R9 = H, C1-4 alkyl] and pharmaceutically
 acceptable salts thereof. The invention also relates to a method of
 treating or reducing inflammation in a mammal in need thereof, which
 comprises administering to said mammal an effective amt. of a compd. or
 compn. of I. Prepn. of compds. of the invention, e.g.
 2-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-
 trifluoromethylphenoxy]benzoic acid, is described. Compds. of the
 invention showed e.g. pos. phospholipase A2 inhibition, generally at 50
 .mu.M levels.

IT 173983-49-8P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (aryl antiinflammatory compd. prepn. and activity)

RN 173983-49-8 CAPLUS

CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-
 (trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




IT 173982-86-0P 173982-87-1P 173982-88-2P
 173982-89-3P 173982-90-6P 173982-91-7P
 173982-92-8P 173982-93-9P 173982-94-0P
 173982-96-2P 173982-97-3P 173982-98-4P
 173982-99-5P 173983-00-1P 173983-01-2P
 173983-02-3P 173983-03-4P 173983-04-5P
 173983-05-6P 173983-06-7P 173983-07-8P
 Searched by Toby Port & Barb O'Bryen

173983-08-9P 173983-09-0P 173983-10-3P
 173983-11-4P 173983-12-5P 173983-13-6P
 173983-14-7P 173983-15-8P 173983-16-9P
 173983-17-0P 173983-18-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (aryl antiinflammatory compd. prepn. and activity)


RN 173982-86-0 CAPLUS

CN Benzoic acid, 2-[2-[[4-bromophenyl)sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173982-87-1 CAPLUS

CN Benzoic acid, 2-[2-[[4-bromophenyl)sulfonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 173982-88-2 CAPLUS

CN Benzoic acid, 2-[2-[(2-naphthalenylsulfonyl)amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173982-89-3 CAPLUS

CN Benzoic acid, 2-[2-[(2-naphthalenylsulfonyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 173982-90-6 CAPLUS

CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]-5-(1,1-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 173982-91-7 CAPLUS

CN Benzoic acid, 2-[2-[(octylsulfonyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 173982-92-8 CAPLUS

CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 173982-93-9 CAPLUS

CN Benzoic acid, 2-[2-[(methanesulfonyl)amino]-4-(trifluoromethyl)phenoxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 173982-94-0 CAPLUS

CN Benzoic acid, 2-[2-[(methanesulfonyl)amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173982-96-2 CAPLUS

CN Benzoic acid, 2-[2-[(phenylsulfonyl)amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173982-97-3 CAPLUS

CN Benzoic acid, 2-[2-[[4-(trifluoromethyl)phenoxy]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173982-98-4 CAPLUS

CN Benzoic acid, 2-[2-[(1-naphthalenylsulfonyl)amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173982-99-5 CAPLUS

CN Benzoic acid, 2-[2-[(phenylmethyl)sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173983-00-1 CAPLUS

CN Benzoic acid, 2-[4-(trifluoromethyl)-2-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 173983-01-2 CAPLUS

CN Benzeneacetic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173983-02-3 CAPLUS


CN Benzoic acid, 2-[2-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173983-03-4 CAPLUS
 CN Benzoic acid, 2-[2-[[[4-methoxyphenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 173983-04-5 CAPLUS
 CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]-4-methoxy- (9CI) (CA INDEX NAME)




RN 173983-05-6 CAPLUS
 CN Benzoic acid, 2-[2-[bis[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]-4-methoxy- (9CI) (CA INDEX NAME)




RN 173983-06-7 CAPLUS

CN Benzoic acid, 2-[2-[bis[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173983-07-8 CAPLUS

CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-bromophenoxy]- (9CI) (CA INDEX NAME)




RN 173983-08-9 CAPLUS

CN Benzoic acid, 2-[2-[[[4-(hydroxymethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173983-09-0 CAPLUS

CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenoxy]-6-methoxy- (9CI) (CA INDEX NAME)




RN 173983-10-3 CAPLUS

CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4-(trifluoromethyl)phenyl]thio]- (9CI) (CA INDEX NAME)




RN 173983-11-4 CAPLUS

CN Benzoic acid, 2-[2-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4,5-dichlorophenoxy]- (9CI) (CA INDEX NAME)




RN 173983-12-5 CAPLUS

CN Benzenesulfonamide, N-[2-[2-(hydroxymethyl)phenoxy]-5-(trifluoromethyl)phenyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 173983-13-6 CAPLUS

CN Benzoic acid, 2-[4,5-dichloro-2-[[[4-chlorophenyl]sulfonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 173983-14-7 CAPLUS

CN Benzeneacetic acid, 3-[[[4-(2,4-dichlorophenoxy)]amino]sulfonyl]-4-(2-carboxyphenoxy)- (9CI) (CA INDEX NAME)




RN 173983-15-8 CAPLUS

CN Benzoic acid, 2-[2-[[[4-(2-hydroxyethyl)phenoxy)]amino]sulfonyl]-4-(2-bromophenoxy)- (9CI) (CA INDEX NAME)




RN 173983-16-9 CAPLUS

CN Benzeneacetic acid, 3-[[[4-(2-bromophenoxy)]amino]sulfonyl]-4-[2-(methoxycarbonyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 173983-17-0 CAPLUS

CN Benzeneacetic acid, 3-[[[4-(2-carboxyphenoxy)]amino]sulfonyl]phenyl]-4-(2-methoxyphenyl)-, .alpha.-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 173983-18-1 CAPLUS

CN Benzoic acid, 2-[4-(trifluoromethyl)-2-[[[4-(2-carboxyphenoxy)]amino]sulfonyl]phenyl]phenyl]- (9CI) (CA INDEX NAME)




IT 173983-50-1

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (aryl antiinflammatory compd. prepn. and activity)

RN 173983-50-1 CAPLUS

CN Benzoic acid, 2-[2-[[[4-(2-carboxyphenoxy)]amino]sulfonyl]phenyl]phenyl]- (trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




IT 173983-40-9P 173983-41-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(aryl antiinflammatory compd. prepn. and activity)


RN 173983-40-9 CAPLUS

CN Benzoic acid, 2-[2-[bis[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-4,5-dichlorophenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 173983-41-0 CAPLUS

CN Benzoic acid, 2-[2-[bis[(4-chlorophenyl)sulfonyl]amino]-4,5-dichlorophenoxy]-, methyl ester (9CI) (CA INDEX NAME)




IT 173983-46-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aryl antiinflammatory compd. prepn. and activity)

RN 173983-46-5 CAPLUS

CN Benzenesulfonamide, N-[2-(2-hydroxyphenoxy)-5-(trifluoromethyl)phenyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



FILE 'CAOLD' ENTERED AT 11:56:13 ON 12 APR 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

Searched by Toby Port & Barb O'Bryen

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L4 STR
L6 37 SEA FILE=REGISTRY SSS FUL L4
L8 0 SEA FILE=CAOLD ABB=ON PLU=ON L6

FILE 'HOME' ENTERED AT 11:56:13 ON 12 APR 2000